

SCHEDULE-AT-A-GLANCE

Sunday, September 28

7:00 a.m. - 8:00 a.m.

Yoga 01 – Sunrise Yoga I

📍 **Nob Hill Room**

7:45 a.m. - 8:30 a.m.

EC 01 – Open Early Career Committee Meeting

📍 **Early Career and Mentoring Lounge; North Lobby**

7:55 a.m. - 9:15 a.m.

PRO 09 – Precision Radiotherapy for Liver and Pancreatic Malignancies: Indications, Techniques and Response Evaluation

📍 **Room 301-304**

8:00 a.m. - 8:30 a.m.

SH 01 – Breast Cancer – Science Highlights

📍 **Room 153**

8:00 a.m. - 8:30 a.m.

SH 02 – Central Nervous System – Science Highlights

📍 **Room 20/21**

8:00 a.m. - 8:30 a.m.

SH 03 – Digital Health Innovation and Informatics – Science Highlights

📍 **Room 159**

8:00 a.m. - 8:30 a.m.

SH 04 – Gastrointestinal Cancer – Science Highlights

📍 **Room 156/158**

8:00 a.m. - 8:30 a.m.

SH 05 – Genitourinary Cancer – Science Highlights

📍 **Room 24**

8:00 a.m. - 8:30 a.m.

SH 06 – Gynecological Cancer – Science Highlights

📍 **Room 307/308**

8:00 a.m. - 8:30 a.m.

SH 07 – Head and Neck Cancer – Science Highlights

📍 **Room 22/23**

Continued on page 3



ARRO hosts Brachytherapy Workshop for Residents

BY DIANE KEAN, ASSISTANT DIRECTOR OF COMMUNICATIONS

NEW THIS YEAR, the Association of Residents in Radiation Oncology (ARRO) hosted a workshop, “Principles and Skills of Brachytherapy: A Resident-focused Workshop,” on Saturday morning, ahead of their annual ARRO Day seminar. More than 100 attendees participated in this dynamic and hands-on learning opportunity. In partnership with ASTRO and the American Brachytherapy Society, ARRO set out to design a workshop that filled a crucial educational gap for many residents. Industry partners Barrigel (Teleflex), Boston Scientific, Elekta, Theragenics, and Varian, A Siemens Healthineers Company, set up stations to demonstrate gynecologic and prostate brachytherapy and spacer techniques. Following an informative didactic training session, residents rotated in groups through the four stations to practice applicator assembly and insertion techniques, work with phantoms directly, and gained hands-on experience with spacer placement and vendor equipment. Each station included a brief industry-led overview followed by supervised skill development with vendor representatives and faculty demonstrations.

The goals of this workshop were for participants to be able to:

1. Identify key procedural steps in performing endometrial and cervical brachytherapy, including applicator selection and placement techniques.
2. Recognize the practical workflow for LDR and HDR prostate brachytherapy, including setup, patient positioning, and catheter or seed placement strategies.
3. Participate in hands-on learning of gynecologic and prostate brachytherapy equipment, including tandems and needles, using practice phantoms.
4. Apply practical tips and troubleshooting techniques for common technical challenges encountered during brachytherapy procedures.
5. Practice rectal spacer gel placement using vendor-provided tools and phantoms.
6. Engage directly with industry partners to learn about equipment and clinical solutions for brachytherapy delivery.

Continued on page 14

Inside
This
Issue

BOARD RECAP

Representatives from the ABR, LPP program, ARRO, ADROP and Journals present to the Board.

Page 5

PRODUCT SHOWCASE

See an overview of featured products and learn more in the Hall B Rotunda.

Page 8

RADIOPHARMACEUTICAL THERAPY

An exciting, new RPT collaborative from ASTRO.

Page 11

SPEED MENTORING SCHEDULE

See details of the sessions being held this morning in the North Lobby.

Page 15

Read more ➤



PLUVICTO[®]

lutetium Lu 177 vipivotide tetraxetan

INJECTION FOR INTRAVENOUS USE

FDA APPROVED

FOR MORE PATIENTS

UNCOVER WHY PRESCRIBING HABITS ARE CHANGING

LEARN MORE AT THE NOVARTIS BOOTH

SCAN TO VISIT
[PLUVICTO-HCP.com](https://pluvicto-hcp.com)



Not actual patients.

 **NOVARTIS**

Novartis Pharmaceuticals Corporation
East Hanover, New Jersey 07936-1080

© 2025 Novartis

6/25

FA-11448332



PLUVICTO[®]

lutetium Lu 177 vipivotide tetraxetan
INJECTION FOR INTRAVENOUS USE

SCHEDULE AT A GLANCE

Sunday, September 29

8:00 a.m. - 8:30 a.m.
SH 08 – Hematologic Malignancies – Science Highlights
📍 *Room 314*

8:00 a.m. - 8:30 a.m.
SH 09 – Lung Cancer/Thoracic Malignancies – Science Highlights
📍 *Room 155/157*

8:00 a.m. - 8:30 a.m.
SH 10 – Nonmalignant Disease – Science Highlights
📍 *Room 160*

8:00 a.m. - 8:30 a.m.
SH 11 – Pediatric Cancer – Science Highlights
📍 *Room 310-312*

8:00 a.m. - 8:30 a.m.
SH 12 – Sarcoma and Cutaneous Tumors – Science Highlights
📍 *Room 305/306/309*

8:10 a.m. - 8:45 a.m.
Welcome 01 – ASTRO CEO Update
📍 *San Francisco Ballroom*

8:45 a.m. - 10:20 a.m.
PS 01 – Presidential Symposium – Rediscovering Radiation Medicine and Exploring New Indications: Session I: Potential, Pitfalls, and a Path Forward for Radiotherapy Beyond Cancer
📍 *San Francisco Ballroom*

9:30 a.m. - 10:30 a.m.
Speed Mentoring 01 – Medical Student Session
📍 *Early Career and Mentoring Lounge; North Lobby*

9:30 a.m. - 10:30 a.m.
Speed Mentoring INT – Speed Mentoring for International Attendees
📍 *Early Career and Mentoring Lounge; North Lobby*

10:20 a.m. - 10:30 a.m.
PS 02 – Presidential Symposium – Rediscovering Radiation Medicine and Exploring New Indications: Session II: Coding Relief: Billing RT for Non-Malignant Diseases
📍 *San Francisco Ballroom*

10:30 a.m. - 11:15 a.m.
PS 03 – Presidential Symposium – Rediscovering Radiation Medicine and Exploring New Indications: Session III: Precision without Incision: The New Era of Functional Radiosurgery
📍 *San Francisco Ballroom*

11:00 a.m. - 3:00 p.m.
ASPP 01 – 2025 Aspiring Scientists and Physicians Program
📍 *Room 154*

11:00 a.m. - 11:30 a.m.
M&G 01 – ASTRO Journal Editors-in-Chief: Ask Them Anything!
📍 *Early Career and Mentoring Lounge; North Lobby*

11:15 a.m. - 12:00 p.m.
PS 04 – Presidential Symposium – Rediscovering Radiation Medicine and Exploring New Indications: Session IV: Past, Present, and Future of Stereotactic Arrhythmia Radiotherapy for Ventricular Tachycardia
📍 *San Francisco Ballroom*

12:00 p.m. - 12:30 p.m.
M&G 02 – Publisher Office Hours I
📍 *Early Career and Mentoring Lounge; North Lobby*

12:00 p.m. - 1:00 p.m.
CL 01 – ASTRO Communities Lounge Program - Global Cancer Prevention: An Interactive Conversation on Vaccine Equity
📍 *ASTRO Communities Lounge*

12:15 p.m. - 1:00 p.m.
ECL 01 – American Board of Radiology (ABR): Transparency in the Certification Process plus Q&A
📍 *Early Career and Mentoring Lounge; North Lobby*

1:00 p.m. - 2:30 p.m.
CT 01 – Clinical Trials
📍 *San Francisco Ballroom*

1:00 p.m. - 2:15 p.m.
PRO 10 – Practical Management Strategies for Advanced Stage Gynecologic Cancer Patients
📍 *Room 301-304*

2:15 p.m. - 3:30 p.m.
PRO 11 – Reviving the Value of Radiation Therapy in Cutaneous Squamous Cell Carcinoma (cSCCa): From Early to Late Stage Disease and Everything in Between
📍 *Room 301-304*

2:15 p.m. - 3:00 p.m.
ECL 02 - 1:1 ASTRO Patient Education on Epic MyChart Care Companion - Learn More!
📍 *Early Career and Mentoring Lounge; North Lobby*

2:30 p.m. - 4:00 p.m.
Workshop 03 – Addressing Access in Breast Cancer – The Impact of Community Patient Navigation from Screening to Survivorship
📍 *Room 151*

2:30 p.m. - 5:45 p.m.
International 01 – Bridging the Gap: Translating the Latest Research into Clinical Practice in Latin America
📍 *Room 159*

2:30 p.m. - 3:45 p.m.
SS 01 – CNS 1: Novel Approaches in Brain Metastases
📍 *Room 152*

2:30 p.m. - 4:00 p.m.
EDU 01 – Emerging Indications for Radiation in Poly-Metastatic Cancers
📍 *Room 305/306/309*

2:30 p.m. - 3:45 p.m.
SS 02 – GI 1: The OPERATIC Side of Rectal Cancer – Organ Preservation, Evaluating Recurrences, and the Immune Checkpoints
📍 *Room 307/308*

2:30 p.m. - 3:45 p.m.
SS 03 – GU 1: Advances in Localized Prostate Cancer
📍 *Room 24*

2:30 p.m. - 3:45 p.m.
SS 04 – GYN 1: Molecular and Precision Medicine for Gynecologic Cancers in Diverse Resource Settings
📍 *Room 160*

2:30 p.m. - 3:45 p.m.
SS 05 – Lung 1: NSCLC Locally Advanced and Oligometastatic
📍 *Room 156/158*

2:30 p.m. - 3:45 p.m.
SS 06 – Radiation and Cancer Biology 1: Factors Mediating Radioresistance
📍 *Room 155/157*

2:30 p.m. - 4:00 p.m.
PQA 01 – Radiation and Cancer Physics, Sarcoma and Cutaneous Tumors
📍 *Hall F*

2:45 p.m. - 4:00 p.m.
EDU 05 – Androgen Deprivation Therapy and Dose Escalation for Prostate Cancer: Lessons from Randomized Trials and the MARCAP Consortium
📍 *Room 20/21*

2:45 p.m. - 4:00 p.m.
EDU 04 – Optimizing Sequencing in Immunotherapy and Radiotherapy for Non-Small Cell Lung Cancer – Clinical and Translational Advances
📍 *Room 310-312*

2: 45 p.m. - 4:45 p.m.
PZ 01 – Paw Zone I
📍 *Exhibit Hall A – Booth 132*

2: 45 p.m. - 4:00 p.m.
EDU 02 – Precision in Practice: The Critical Role of Radiation Dosimetry in Radiotherapeutic Pharmaceuticals
📍 *Room 22/23*

2: 45 p.m. - 4:00 p.m.
EDU 03 – Prevention and Management of RT-related Skin Toxicities
📍 *Room 314*

3:00 p.m. - 4:00 p.m.
Speed Mentoring 02 – Speed Mentoring II
📍 *Early Career and Mentoring Lounge; North Lobby*

4:00 p.m. - 4:30 p.m.
SMMU 01 - ASTRO 2025 Social Media Meet Up
📍 *South Lobby*

4:00 p.m. - 4:45 p.m.
CL 02 - ASTRO Communities Lounge Program - Community Forum: Partnering with LGBTQ+ Community Organizations to Improve Cancer Care
📍 *ASTRO Communities Lounge*

4:00 p.m. - 5:00 p.m.
EC 02 – Navigating Parenthood in Early Career: A Panel Discussion from the ASTRO Early Career Committee
📍 *Early Career and Mentoring Lounge; North Lobby*

ASTRO Daily News 2025
Issue Number 2 | Sunday Edition

Publisher:
Vivek S. Kavadi, MD, MBA, FASTRO

Editorial Director:
Anna M. Arnone

Managing Editor:
Diane Kean

Design/Production:
Jaimie Hernandez

Contributing Editors:
Lisa Braverman
Alex Carrigan
Jennifer Jang

SCHEDULE AT A GLANCE

Sunday, September 29

4:45 p.m. - 6:00 p.m. EDU 11 – ASTRO/SNMMI Joint Session: Unlocking Success in Radiopharmaceutical Therapy: Collaboration between Radiation Oncology, Nuclear Medicine and Industry 📍 <i>Room 156/158</i> 4:45 p.m. - 6:00 p.m. SS 07 – Breast Cancer 1: Redefining Radiation Schedules: Hypofractionation and APBI Across the Breast Cancer Spectrum 📍 <i>Room 301-304</i> 4:45 p.m. - 6:00 p.m. International 02 – Establishing a Global Oncology Program: Overcoming Challenges, Leveraging Opportunities, and Learning from Success 📍 <i>Room 20/21</i>	4:45 p.m. - 6:00 p.m. SS 08 – GU 2: Bladder and Post-Prostatectomy Radiation 📍 <i>Room 24</i> 4:45 p.m. - 6:00 p.m. SS 09 – Head and Neck 1: Highest-Rated Abstracts for Virally-Mediated Head and Neck Cancer 📍 <i>Room 305/306/309</i> 4:45 p.m. - 6:00 p.m. PQA 02 – Lung Cancer/Thoracic Malignancies, Patient Reported Outcomes/QoL/Survivorship, Pediatric Cancer 📍 <i>Hall F</i> 4:45 p.m. - 6:00 p.m. SS 10 – Patient Reported Outcomes/ QoL/Survivorship 1: Fixing What's Broken and Reaching for the Sky 📍 <i>Room 314</i>	4:45 p.m. - 6:00 p.m. EDU 10 – Pediatric Neuro-Oncology Tumor Board: Multidisciplinary Perspectives on Challenging Pediatric Brain Tumor Cases 📍 <i>Room 22/23</i> 4:45 p.m. - 6:00 p.m. EDU 09 – Providing Equitable Care to Pregnant Patients 📍 <i>Room 310-312</i> 4:45 p.m. - 6:00 p.m. EDU 07 – Radiation Resistance and Metabolic Reprogramming 📍 <i>Room 307/308</i> 4:45 p.m. - 6:00 p.m. SS 11 – Radiation and Cancer Physics 1: BEST of PHYSICS 📍 <i>Room 155/157</i> 4:45 p.m. - 6:00 p.m. EDU 08 – Radiotherapy for Leukemia: Past, Present and Future 📍 <i>Room 160</i>	4:45 p.m. - 6:00 p.m. EDU 06 – Real-Time, Real-World Impact: How a Radiation Oncology Quality Collaborative, MROQC, is Shaping the Future of Radiation Oncology 📍 <i>Room 152</i> 4:45 p.m. - 6:00 p.m. SS 12 – Sarcoma 1: From Margins to Mainstream: Advances in our Understanding of Rare Bone, Cutaneous, and Connective Tissue Tumors 📍 <i>Room 153</i> 5:00 p.m. - 6:00 p.m. ARRO 05 – ARRO Mentoring and Networking Reception 📍 <i>Early Career and Mentoring Lounge; North Lobby</i> 5:30 p.m. - 8:00 p.m. Meet Up 01 – LGBTQIA+ and Allies Meet Up 📍 <i>Golden Gate C1</i>
--	--	---	---



Presidential Symposium | 8:45 a.m. - 12:00 p.m.

LED BY ASTRO PRESIDENT SAMEER KEOLE, MD, FASTRO, this year’s Presidential Symposium embodies the Annual Meeting theme of Rediscovering Radiation Medicine and Exploring New Indications. The speakers represent a variety of specialties and will help spark thinking differently about where we are going and how to get there. Specifically, this year’s Presidential Symposium will highlight the existing and emerging data on radiation therapy for non-cancer indications featuring multidisciplinary experts on treatment for musculoskeletal (e.g., plantar fasciitis, osteoarthritis), cardiac (e.g., arrhythmias, early heart failure) and functional neurologic (e.g., tremors from Parkinson’s disease) conditions.

Symposium Introduction | 8:45 a.m. - 8:50 a.m.

- ASTRO President Sameer Keole, MD, FASTRO, Mayo Clinic, Phoenix

Session I: Potential, Pitfalls and a Path Forward for Radiotherapy Beyond Cancer | 8:50 a.m. - 10:20 a.m.

Speakers:

- Radiotherapy Beyond Cancer: Opportunities and Challenges
 - Jarad Martin, MD, MB, ChB, PhD, BSc, GAustMS – Calvary Mater Newcastle Hospital, Newcastle
- Dupuytren’s Disease and Radiotherapy: A Surgical View
 - Paul Werker, MD, PhD – University Medical Center Groningen, Groningen
- Radiotherapy for Osteoarthritis: The Who, The How and The Why
 - Heidi Prather, DO – Weill Cornell Medicine/New York Presbyterian, New York
- Translating Oncology Lessons beyond Cancer
 - Gopal Bajaj, MD, MBA, FASTRO – Inova Schar Cancer Institute, Fairfax
- Panel Discussion
 - Speakers will be joined by Jan Kriz, MD, PhD – Clemens Hospital, Muenster, for a discussion.

Session II: Coding Relief: Billing RT for Nonmalignant Diseases | 10:20 a.m. - 10:30 a.m.

- Coding Relief: Billing RT for Nonmalignant Diseases
 - Speaker: Amar Rewari, MD, MBA, FASTRO – Luminis Health, Annapolis

Session III: Precision without Incision: The New Era of Functional Radiosurgery | 10:30 a.m. - 11:15 a.m.

- Classical Movement Disorders and Connectomics: Image-Guided Radiosurgery Reimagined
 - Markus Bredel, MD, PhD – University of Miami Sylvester Comprehensive Cancer Center, Miami
- The Evolving Frontier of Functional SRS: Psychiatric Disease, Pain, and Beyond
 - Evan Thomas, MD, PhD – Renaissance Institute for Precision Oncology & Radiosurgery, Winter Park
- Panel Discussion
 - Sameer Keole, MD, FASTRO – Mayo Clinic, Phoenix

Session IV: Past, Present, and Future of Stereotactic Arrhythmia Radiotherapy for Ventricular Tachycardia | 11:15 a.m. - 12:00 p.m.

Speakers:

- Clifford Robinson, MD, FASTRO – Washington University in St. Louis, St. Louis
- Phillip Cuculich, MD – Washington University St. Louis, St. Louis 



Representatives from the ABR, LPP Program, ARRO, ADROP and ASTRO Journals Present to ASTRO Board of Directors

EACH YEAR, ONE OF THE ASTRO BOARD of Directors' three in-person meetings is held immediately prior to the Annual Meeting. Day two of the Board Meeting included a presentations from several important ASTRO groups and others.

Saturday, September 27, presentations began with Michael Yunes, MD, Associate Executive Director of the American Board of Radiology for Radiation Oncology. Dr. Yunes emphasized that the ABR's certification role benefits patients. He explained the Holman Pathway, which offers a quicker route to certification while ensuring academic and clinical time are not sacrificed. Dr. Yunes emphasized that while pass rates for radiation oncology are higher than many other specialties, individuals who do not pass a portion of the exam may retest at the next exam period — they do not need to wait another year.

ASTRO's Leadership Pathway Program (LPP) participants provided updates on their progress in the program, and associated projects they had undertaken.

Kristina Mirabeau-Beale, MD, MPH, described her twin emphases on advocacy and communications. She has worked with various teams to understand how ASTRO creates its messaging, balances its values and needs, and utilizes social media to disseminate news, all with a focus on the Radiation Oncology Case Rate (ROCR) Program.

Ashish Patel, MD, MBA, spent his time in the LPP program working with the Clinical Affairs and Quality Council (CAQC). Dr. Patel helped execute a survey to inform the development of more robust APEX standards. Screening patients for financial toxicity, as well as other treatment barriers, emerged as a priority.

Elizabeth Nichols, MD, worked in the Health Policy track on the development of a

hypofractionation calculator. In conjunction with the Health Policy team, this calculator has particular emphases on breast and prostate cancer treatments.

Lara Hathout, MD, FRCPC, focused her project on an environmental scan of harassment in medicine. Dr. Hathout noted that harassment is a widespread issue, and that it is important to understand the impact of harassment on individuals and on the profession. The goal of the project, Dr. Hathout said, was "creating a safer and more inclusive professional environment."

Jenna Kocsis, MD, Chair of the Association of Residents in Radiation Oncology (ARRO) presented the results of the most recent graduating resident survey. Dr. Kocsis explained that there had been a decrease in the number of unfilled positions; there were 12 unfilled positions last year and five this year. Additionally, there was a notable downtrend in the number of residents who said the job market was "tough this year." One percent of residents were dissatisfied with the position they accepted. More exposure to brachytherapy was noted as an area for growth, which was initially addressed with Saturday's superbly attended Brachytherapy Workshop.

The morning's presentations concluded with updates from Albert Attia, MD, President of the Association for Directors of Radiation Oncology Programs (ADROP); Rachel Jimenez, MD, Editor-in-Chief of *Advances in Radiation Oncology*; Robert Amdur, MD, Editor-in-Chief of *Practical Radiation Oncology*; and Sue Yom, MD, PhD, FASTRO, Editor-in-Chief of the Red Journal. These leaders of the field gave updates on the successful programs they lead and will be available throughout the meeting to interact with attendees. [A](#)

STREET TALK

What sessions and events are you most excited to attend at this year's Annual Meeting?



"I'm looking at CNS sessions talking about advancements in glioma management as well as other primary and metastatic brain tumors. I'm also interested in the Keynote Session on Monday."

– Raj Upadhyay, MD, Moffitt Cancer Center



"I'm applying for residencies, so I'm particularly interested in the Speed Mentoring sessions. I'm looking forward to meeting mentors and people who are going to guide us through the start of our journeys in our residency."

– Samaan Jukaku, MBBS, MVR Cancer Centre & Research Institute



"I'm excited to exchange experiences with great, great radiation oncologists and have many interactive collaborations with the international community."

– Cristiane Almeida, MD, Radioterapia Sao Sebastiao

CORRECTION

The Sunday print edition incorrectly stated the date of Education Session 39, "Update on ASTRO/ASCO/SSO Postmastectomy Radiation Therapy Guideline: A Case-Based Interactive Discussion." **The session will be held Tuesday, September 30 at 12:45 p.m. in Room 24.**



Exhibit Hall opens today at 10:00 a.m.

Nearly 200 exhibitors look forward to visiting with you, starting today through Tuesday, grand opening of the Hall is 10:00 a.m. today! Mingle with exhibitors over beverages and snacks during the extended break tomorrow afternoon at 4:00 p.m. during the Exhibit Hall Networking reception (all in-person attendees received a beverage ticket with registration materials). Here you will also find the Industry-Expert Theaters, scheduled over the next few days.

INDUSTRY SATELLITE SYMPOSIA

SUNDAY, SEPTEMBER 28

6:15 p.m. - 7:15 p.m.: Dinner and Program
A Treatment Option for Patients With a Certain Type of Advanced Cervical Cancer

Location: San Francisco Marriott Marquis | Golden Gate B
780 Mission Street, San Francisco, CA 94103

CME Credits: This is a non-CME program.

This activity is independently organized by Merck & Co., Inc.

6:30 p.m. - 8:00 p.m.: Dinner and Symposium
Shaping the Future: The Evolving Role of Radiologists in Lower-Grade Glioma Care

Location: San Francisco Marriott Marquis | Golden Gate A
780 Mission Street, San Francisco, CA 94103

CME Credits: Medscape, LLC designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity is supported through an educational grant from Servier.

INDUSTRY-EXPERT THEATERS

SUNDAY, SEPTEMBER 28

12:00 p.m. - 1:00 p.m.

📍 Theater 1 BioProtect <i>Beyond the Gels: It's Time to Rethink Your Rectal Spacer</i>	📍 Theater 2 Blue Earth Diagnostics, Inc. <i>POSUMA (flotufolastat F 18) Injection Overview and Case Study Review</i>	📍 Room 1/2, Exhibition Level GE HealthCare <i>Converging Beams: Radiation Therapy meets Radioligand Therapy</i>
--	--	---

2:00 p.m. - 3:00 p.m.

📍 Theater 1 GammaTile <i>Reproducibility Matters: Clinical Insights from Radiation Oncologists Using GammaTile</i>	📍 Theater 2 PreludeDx <i>From Clin-Path to Precision in Early-Stage Breast Cancer: How New Genomic and Multi-Omic Risk Assessments Impact Your Radiation Treatment Decisions and Your Practice</i>	📍 Room 1/2, Exhibition Level Accuray <i>Case-Based Contouring and Treatment Planning with Clinical Experts</i>
--	--	--

TURNKEY SOLUTIONS for radioisotope production in nuclear medicine




Best™ Model BG-95

SUB-COMPACT SELF-SHIELDED CYCLOTRON FOR PRODUCTION OF: ^{18}F FDG, Na^{18}F , ^{18}F -MISO, ^{18}F LT, ^{18}F -CHOLINE, ^{18}F -DOPA, ^{18}F -PSMA, ^{13}N AND ^{68}Ga



Best™ Model B25p
CYCLOTRON



Best™ Model 6-15 MeV
COMPACT HIGH CURRENT/VARIABLE ENERGY PROTON CYCLOTRON



Best™ Model B35ADP
ALPHA/DEUTERON/PROTON CYCLOTRON

Cyclotrons of Varying Energies


B100 CYCLOTRON	7.5 MeV	Capable of producing: ^{18}F FDG and Na^{18}F • Single or batch dose production • Integrated self-shielded cyclotron, chemistry module and FDG QC module • Complete production lab in a 5 x 5 meter area
BG-95 CYCLOTRON	1-9.5 MeV	Low energy, self-shielded compact system capable of producing: ^{18}F FDG, Na^{18}F , ^{18}F -MISO, ^{18}F LT, ^{18}F -Choline, ^{18}F -DOPA, ^{18}F -PSMA, ^{13}N and ^{68}Ga
Best CYCLOTRONS	1–3 MeV	Deuterons for materials analysis*
	70–200 MeV	For Proton Therapy*
	3–90 MeV	High current proton beams for neutron production and delivery*
B6-15 CYCLOTRON	1–15 MeV	Proton only, capable of high current up to 1000 Micro Amps, for medical radioisotopes
B25 CYCLOTRON	20, 15–25 MeV	Proton only, capable of high current up to 1000 Micro Amps, for medical radioisotopes
B25u–35adp CYCLOTRON	25–35 MeV	Proton or alpha/deuteron/proton, capable of high current up to 1000 Micro Amps, for medical radioisotopes
B35 CYCLOTRON	35 MeV	Proton only system for medical radioisotopes production
B70/70adp CYCLOTRON	35–70 MeV	Proton only or alpha/deuteron/proton systems, capable of high current up to 1000 Micro Amps, for medical radioisotopes

*Some products are under development and not available for sale currently.



Ion Rapid Cycling Medical Synchrotron (IRCMS) 200–400 MeV Variable Energy for Proton to Carbon Heavy Ion Radiation Therapy

**Racetrack Synchrotron—
Smaller Area Footprint**





Best™ Model 200p
CYCLOTRON FOR PROTON THERAPY*

*Patent pending

TeamBest Global Companies ©2025



Visit the Product Showcase located in the Halls A and B and also available on the AM Portal to learn about the products featured in the Product Showcase.

 Company Name: Accuray Incorporated Booth Number: 525	 Company Name: Akumin Booth Number: 1633 Product Name: Akumin AXIS™ LINAC	 Company Name: CQ Medical Booth Number: 313 Product Name: Lithotomy AirShuttle™
 Company Name: CQ Medical Booth Number: 313 Product Name: Pronumbra	 Company Name: Elekta Booth Number: 1407 Product Name: Elekta ONE Planning	 Company Name: GE HealthCare Booth Number: 325 Product Name: Intelligent RT™ (iRT)
 Company Name: Lantheus Booth Number: 1425	 Company Name: Leo Cancer Care Booth Number: 2325 Product Name: Marie®	 Company Name: MIM Software, A GE Healthcare Company Booth Number: 225 Product Name: MIM Maestro
 Company Name: NELCO Booth Number: 215	 Company Name: Novocure, Inc. Booth Number: 515	 Company Name: Radformation Booth Number: 601 Product Name: QuickCode
 Company Name: Sensus Healthcare Booth Number: 1301 Product Name: SRT-100 Vision™	 Company Name: Shared Imaging, LLC Booth Number: 237 Product Name: Mobile PET/CT & Cardiac Imaging Solutions	 Company Name: Standard Imaging Booth Number: 501 Product Name: IMSure3D™ Software
 Company Name: Sumitomo Pharma America, Inc. Booth Number: 204 Product Name: ORGOVXY	 Company Name: Sun Nuclear, a Mirion Medical Company Booth Number: 1724 Product Name: Plan AI™	 Company Name: XpeditMD, Inc. Booth Number: 235 Product Name: XpeditMD

ASTRO GUIDELINE UPDATE: PRACTICAL GUIDANCE ON RADIOTHERAPY FOR BRAIN CANCERS

ASTRO'S CLINICAL PRACTICE GUIDELINES translate evolving evidence into day-to-day decisions. This year's Annual Meeting features three interactive Education sessions that bring new or updated guidance into conversation with experts, showcasing how the evidence surrounding optimal treatments is evolving. This year's program features updated guidelines on postmastectomy radiation therapy (PMRT) and high-grade gliomas, and a focused update on rectal cancer. Whether your practice is community-based or academic, these sessions aim to clarify areas of uncertainty. Additionally, the guidelines and related sessions organize a tremendous amount of data into a format that can be quickly referenced. The corresponding publications can be found in ASTRO's clinical practice journal, *Practical Radiation Oncology* — both in print and online at practicalradonc.org.

Radiation Therapy for WHO Grade 4 Gliomas EDU 20 | Monday, 10:45 a.m.–12:00 p.m. | Room 307/308

ASTRO's new glioma guideline replaces the 2016 glioblastoma guidance, reflecting major advances in molecular classification and treatment. Led by moderators Debra Yeboa, MD and Joseph Bovi, MD, panelists will cover evidence-based recommendations for adjuvant chemoradiation, reirradiation, and integration with systemic and adjunctive therapies. Using case examples, speakers will demonstrate how to select dose-fractionation regimens, define target volumes and navigate multidisciplinary decision-making. Attendees will leave with a clearer framework for managing these aggressive tumors and aligning their practice with the latest standard of care.

"As oncologists, high-grade gliomas are among the most challenging cancers we see, and radiation therapy plays a vital role in improving outcomes for these patients," said Joseph A. Bovi, MD, chair of the guideline task force and a radiation oncologist at ThedaCare Regional Cancer Center in Appleton, Wisc. "This guideline brings together the best evidence across multiple disciplines to support coordinated care that includes surgery, radiation therapy, systemic therapies, alternating electric field therapy and supportive care."

Debra Nana Yeboa, MD, vice chair of the guideline task force and an associate professor of radiation oncology at the University of Texas MD Anderson Cancer Center in Houston, said, "our goal was to equip clinicians with a clear, robust framework for shared decision-making with their patients, while also highlighting areas where research is needed to move the field forward." "Progress in personalized medicine, biomarker discovery, and advanced treatment techniques could help us change outcomes for patients, particularly those in underserved populations."

Key recommendations of the guideline are:

1. Fractionated radiation therapy (RT) is recommended for patients who have undergone biopsy or resection, based on several randomized controlled trials finding increased survival with RT compared to chemotherapy or supportive care alone. The guideline discusses optimal timing and fractionation schedules for adjuvant RT.
2. Temozolomide (TMZ) chemotherapy given concurrently with RT and following RT is also recommended after biopsy or resection. Alternating electric field therapy is conditionally recommended after RT for patients with tumors in the upper regions of the brain (i.e., supratentorial disease).
3. Recommendations outline suggested dose-fractionation regimens for RT guided by the patient's age and functional status. Shorter radiation courses are conditionally recommended for elderly patients and those with indications of frailty. For patients with severe frailty, who have notably increased risk of complications from intensive treatments, supportive care in lieu of chemoradiation is conditionally recommended following a multidisciplinary, patient-centered discussion. Supportive care, including palliative services, is also discussed in the context of helping patients manage symptoms during and after treatment. The guideline also discusses recommended treatment techniques and target volumes and notes the importance of daily image guidance during RT.
4. Reirradiation for WHO grade 4 diffuse glioma recurrence is conditionally recommended for selected adult patients with good functional status, following a multidisciplinary, patient-centered discussion. The guideline also reviews indications and techniques for reirradiation including diagnostic and treatment considerations, as well as systemic therapy in the reirradiation setting.

The task force also reviewed the literature on health disparities and adult high-grade glioma, calling to attention the need for more studies that examine barriers to access and the need to increase clinical trial enrollment for underserved populations. [A](#)

RTOG Foundation Hosts Overview Session Engaging Early Career Investigators

THE RTOG FOUNDATION (RTOGF), a nonprofit organization that conducts clinical trials with the goal of improving outcomes for cancer patients, will be hosting an educational and networking session at this year's ASTRO Annual Meeting. The session titled "Clinical Research & RTOG Foundation – How Can You Get Involved" will be occurring tomorrow, Monday, September 29 starting at 8:00 a.m. in the ASTRO Early Career and Mentoring Lounge in the North Lobby.

The presentation will be led by RTOGF Board Members, Kristin Higgins, MD, the Chief Clinical Officer for City of Hope Cancer Center in Atlanta, and Seth Rosenthal, MD, FASTRO, a radiation oncologist at Sutter Health in Sacramento. They will provide overview information



on what the RTOGF is, the history of RTOGF and NRG Oncology, and their organizational structure. During this presentation, they will review the many disease sites and specialties that RTOGF is an international leader of research in, including: brain tumors, head and neck cancers, genitourinary cancers, gastrointestinal cancers, thoracic/lung cancers, oligometastatic cancers, proton therapy, and stereotactic radiosurgery. The presenters will highlight the many successes in clinical trials that have stemmed from research through RTOGF — including the combination of radiation therapy and sorafenib improving survival in hepatocellular carcinoma and the combination of radiation therapy and cetuximab for improved progression-free survival in resected head and neck cancer.



The latter half of this presentation will discuss RTOG's mission for inclusion of early career investigators within our organization. Involvement with clinical research can be an important component of professional development and ongoing personal career satisfaction. Drs. Higgins and Rosenthal will review some steps of how to get started with RTOGF, both organizationally and through our clinical trial process.

Following the initial presentation, this session will open the floor to questions and group networking. RTOGF Board Members, including Quynh Le, MD, FASTRO, (board chair) and Mitch Machtay, MD, (board president), will be present during the entire session and will be available to answer questions and discuss topics further with attendees.

RTOGF is dedicated to the advancement and mentorship of our future leaders in radiation-based clinical research and looks forward to providing this session as a means for investigators to learn more and open discussions about working with RTOGF in the future. [A](#)

Second CEO Council Meeting Held at ASTRO 2025



Yesterday, ASTRO CEO Vivek S. Kavadi, MD, MBA, FASTRO, hosted the second CEO Council Meeting. Dr. Kavadi spoke on ASTRO's International Strategy, including developing initiatives to grow ASTRO's international presence, emphasizing the importance of global engagement. Dr. Kavadi also provided updates regarding the Radiation Oncology Case Rate (ROCR) Act and the ASTRO Economics of Oncology Project.

Dr. Kavadi was joined by Suzanne Winter, President & CEO, Accuray; Rainer Birkenbach, CEO, Brainlab; Michael Galbus, COO, CQ Medical; Jakob Just-Bomholt, President & CEO, Elekta; Olivier Legrain, CEO, IBA; Tina Yu , CEO & President, Mevion Medical Systems; Luis Rivera, EVP Mirion Medical/President Sun Nuclear RTQA, Sun Nuclear; Frank Leonard, EVP & President, Novocure; Johan Löf, Founder & CEO, RaySearch; Arthur Kaendl, Head of Varian, Varian/Siemens Healthineers; Joe Deister, VP the Americas, VisionRT; and ASTRO staff Kathy Peters, Director, Corporate Relations and Development, and Karen Davis, VP, Business Development and Marketing.

INTRODUCING...

α BOLD NEW CHAPTER in radiation oncology

If you're exploring succession planning or seeking an alternative ownership model that protects your autonomy, preserves your legacy, and unlocks capital for growth, **this is your moment.**



Radiation Business Solutions proudly presents **Anoma Cancer Collective (ACC)**, an innovative new model that offers a nonprofit path for physician owners and hospital oncology programs.



ASTRO 2025

We're offering **private informational sessions** at ASTRO - **Sunday and Monday only** - to discuss how ACC can support your center or hospital program.

Spots are limited. Scan the QR code here to book your time or visit booth #1308 to learn more.

And if you're a board-certified radiation oncologist seeking meaningful, mission-driven work, we're also recruiting a full-time physician to travel between our nonprofit centers. Learn more during your session or drop by the booth for more details.

Why You Should Join ASTRO's New Radiopharmaceutical Therapy Learning Collaborative

BY RANDI KUDNER, ASSISTANT DIRECTOR, QUALITY IMPROVEMENT

RADIOPHARMACEUTICAL THERAPY IS RESHAPING THE LANDSCAPE

of cancer care, offering targeted treatment options that combine the precision of molecular medicine with the therapeutic power of radiation. This modality is rapidly moving from research into standard practice.

As demand grows, so does the need for practices to be ready — not only to provide these therapies safely and effectively but also to contribute to the clinical trials that will define best practices and expand access for patients. That's where ASTRO's new Learning Collaborative for Radiopharmaceutical Therapy comes in. This initiative is designed to help interested practices stand up a new RPT service line and/or accelerate their readiness for clinical trials with confidence, efficiency and compliance.

The Growing Importance of Radiopharmaceutical Therapy

Radiopharmaceutical therapy agents are already transforming treatment for advanced prostate cancer and neuroendocrine tumors. Pharmaceutical companies are investing in development pipelines, and clinical trials are expanding worldwide. However, offering these therapies is complex. They require:

- **Specialized infrastructure** for handling and administering radioactive drugs
- **Stringent regulatory compliance** across safety, radiation protection, and radiopharmacy standards
- **Cross-departmental coordination** among radiation oncology, nuclear medicine, radiation safety, and pharmacy teams
- **Patient education and safety protocols** before, during, and after treatment

For many practices, these requirements can feel overwhelming — especially when added to the pressure of staying current with trial opportunities and ensuring your team is aligned with best practices. The Learning Collaborative is designed to help overcome these barriers.

What is ASTRO's Radiopharmaceutical Therapy Learning Collaborative? This opportunity is more than a course or webinar series. It's an interactive program that brings together a network of clinicians with a shared goal: to learn from each other, implement evidence-based strategies, and accelerate improvement in radiopharmaceutical therapy.

This first series has two pathways:

1. **Standing Up a New Service Line** – Guiding you through the operational, regulatory and clinical steps needed to establish a sustainable RPT program.
2. **Clinical Trial Readiness** – Helping your organization identify, prepare for, and successfully participate in radiopharmaceutical therapy trials.

Participants will gain access to experienced leaders, peer-to-peer learning sessions, practical tools and templates, and implementation support tailored to their unique circumstance.

Why Focus on Standing Up a New Service Line?

Launching a radiopharmaceutical therapy program is a major undertaking, involving clinical, operational and financial considerations. Common challenges include:

- Regulatory compliance – Navigating state and federal radiation regulations and NRC licensing
- Interdisciplinary coordination – Aligning referring physicians, nuclear medicine, medical oncology, pharmacy and nursing workflows
- Patient safety – Ensuring protocols for radiation protection, contamination control and post-treatment guidance
- Financial sustainability – Understanding reimbursement models, coding and cost management

The Learning Collaborative breaks this down into actionable steps. Participants will discuss how to:

- Create a service line business plan with realistic timelines and cost projections
- Design facility workflows that meet safety and efficiency standards
- Develop training plans for all team members, from physicians to technologists
- Build a patient education and consent process that prioritizes safety and understanding
- Ensure reimbursement readiness for radiopharmaceutical therapy services

By the end of the program, you'll have a comprehensive understanding of what's involved and the confidence to operationalize your service line effectively.

Why Focus on Clinical Trial Readiness?

Clinical trials are the engine that drives innovation. By participating in trials, your practice can:

- Offer new therapies to patients who may have limited options
- Build internal expertise with new agents and protocols
- Shape the future by contributing data and insights

However, clinical trial readiness requires preparation:

- Are your staff trained for trial-specific requirements?
- Do you have access to the equipment required for clinical trials?
- Do you have the proper workflows for data collection and reporting?

With the support of expert leaders and peers, your team can move from uncertainty to confidence — ready to open trials and enroll patients faster.

What Makes This Collaborative Different?

Unlike traditional educational programs, the Learning Collaborative model emphasizes shared learning and practical application. Here's what sets it apart:

- Expert leaders – Nationally recognized radiopharmaceutical therapy experts guide the sessions.
- Peer learning – Connect with other organizations facing similar challenges and exchange best practices.
- Ongoing support – Create networks with peers, experts and ASTRO for future questions and development.

The Bottom Line

The momentum behind radiopharmaceutical therapy is undeniable. Every year, new agents move closer to FDA approval. Whether you're starting from scratch or enhancing an existing program, this collaborative meets you where you are. Health systems that prepare now will be positioned to:

- Lead in innovative cancer care
- Improve patient access to life-extending therapies
- Advance research and shape clinical standards

By joining ASTRO's Learning Collaborative, you're not just attending a training — you're investing in your practice's future and in better outcomes for patients. Be the practice that's ready, capable and confident. 



Register now and start building your radiopharmaceutical therapy roadmap today.



2025 Research Grants Accelerate New Indications for RT

BY EMILY CONNELLY, SENIOR GOVERNANCE AND RESEARCH OFFICER

THIS YEAR, THE RADIATION ONCOLOGY INSTITUTE (ROI) — the ASTRO Foundation — awarded its 2025 Innovation Awards to four teams of pioneering researchers dedicated to exploring new indications for radiation therapy (RT). The aim of these grants is to advance radiation medicine, offering new hope to patients and opening up novel avenues for treatment of non-cancerous conditions.

The Innovation Award winners will be honored on Monday, September 29, in a brief ceremony before the keynote address. The investigative teams and their funded projects are:



Carmen Bergom, MD, PhD, and Ali Javaheri, MD, PhD, Washington University in St. Louis, “Preclinical Studies to Optimize the Use of Radiotherapy for Heart Failure”



Khashayar Fattah, MD, and faculty mentor Robert Timmerman, MD, FASTRO, University of Texas Southwestern Medical Center, “Optimizing Target Delineation and Motion Control in Cardiac Radioablation”



Michelle Iocolano, MD, and faculty mentor John Plastaras, MD, PhD, University of Pennsylvania, “Low Dose RT for Osteoarthritis and Aromatase Inhibitor-Related Joint Pain”



Sue Yom, MD, PhD, and Mary Helen Barcellos-Hoff, PhD, University of California, San Francisco, “Combining TGF- β Inhibition with Radiation Therapy for Inoperable Keloids”

All of this year’s ASTRO and ROI research grants and fellowships award winners will be recognized together Monday morning at 9:00 a.m. to celebrate our shared science successes and launch a more collaborative approach for the future.

Expanding indications for radiation therapy is an area of research with immense potential for the future of the field as evidenced by the synergy with this year’s Annual Meeting theme. Two of this year’s Innovation Award winners are presenting abstracts at ASTRO 2025 that serve as a foundation for their research supported by their new grants from ROI. Make time in your schedule to learn more about the groundbreaking research of these talented investigative teams.

Dr. Bergom is presenting “The Inflammatory State of the Heart at the Time of Radiotherapy May Drive Cardiotoxic vs. Therapeutic Responses” on Monday, September 29 from 5:00 p.m. - 6:00 p.m. during Poster Q&A 06 - Radiation and Cancer Biology, Health Care Access and Engagement in Hall F. Dr. Bergom is sharing results of the team’s promising work showing that radiation treatment to the heart may improve heart function in inflammatory heart failure. Their research challenges the long-held belief that RT exposure to

the heart is always harmful. This presentation builds upon their prior research demonstrating that localized heart RT (5 Gy) in models of inflammatory heart failure can improve cardiac outcomes and survival by increasing the dose to 16 Gy and examining differences in heart substrate characteristics between failing and non-failing hearts. Their most recent results suggest that differences in inflammatory changes in failing versus non-failing hearts could provide insights into personalized approaches for RT treatment in heart failure in the future.

With the 2025 Innovation Award from ROI, Dr. Bergom and co-PI Dr. Javaheri will continue their work on preclinical models to find the best radiation dose and schedule to improve heart function in HF, study whether FLASH RT can provide the same benefits to the heart while lowering the risk of damage, and identify biomarkers to predict which patients with HF are mostly likely to experience the best outcomes from RT.

Dr. Fattah is presenting “Incorporating Electroanatomic Mapping Data into Radiation Treatment Planning for Stereotactic Cardiac Radioablation: A One-Year Follow-up” on Tuesday, September 30 from 2:30 p.m. - 3:45 p.m. during Poster Q&A 08 - Gastrointestinal Cancer, Nonmalignant Disease, Palliative Care in Hall F. Cardiac radioablation using stereotactic body radiation therapy (SBRT) is a promising and evolving treatment option for patients with ventricular tachycardia (VT) who have not responded to standard treatments, but challenges remain that prevent wider adoption, including reducing the amount of healthy tissue being irradiated and accounting for cardiac motion during treatment. At ASTRO 2025, Dr. Fattah is reporting on behalf a team composed of radiation oncologists led by Sunil Krishnan, MD, FASTRO, and electrophysiologists from UT Health Houston, on their initial efforts to incorporate electroanatomic mapping (EAM) data, which provides detailed and accurate information for localizing VT circuits in the heart, into treatment planning for two patients with VT who had previously undergone radiofrequency ablation but had not responded to the initial treatment. They integrated EAM data with CT simulation to more accurately define the treatment target. Both patients in the study had positive outcomes, responding quickly to the SBRT delivered using the team’s novel treatment planning method, and sustaining complete resolution of VT without recurrence or treatment-related side effects after nine months. This new approach could serve as a critical bridge between functional information gathered by electrophysiologists and anatomic imaging information used by radiation oncologists to more precisely treat the source of VT with radiation therapy.

Dr. Fattah, now at UT Southwestern under the mentorship of Dr. Timmerman, is using the grant from ROI to develop software for the integration of electrophysiology data into the treatment planning system in collaboration with a group of electrophysiologists. They will also evaluate the feasibility of using real-time imaging and electrocardiogram monitoring to synchronize treatment delivery with the diastolic phase of the cardiac cycle. Together, these innovations could help reduce treatment planning volumes, minimize side effects and toxicity, and potentially expand the number of patients with VT and other cardiac arrhythmias who could benefit.

ROI is proud to support all four award-winning teams composed of the best and brightest investigators who are pushing the boundaries of the field to help us achieve our vision of a world where every person has access to the best radiation therapy to live a longer, healthier life. The 2025 ROI Innovation Awards to expand indications for radiation therapy are generously supported in part by a grant from Varian, a Siemens Healthineers Company. 



Take a session break and enjoy some cuddle time with our lovable canine companions. Just a wag away, the Paw Zone is the perfect pick-me-up!

📍 Exhibit Hall, Booth 132, Hall A

Sunday, September 28 2:45 p.m. - 4:45 p.m.

Monday, September 29 12:00 p.m. - 2:00 p.m.

Tuesday, September 30 11:30 a.m. - 1:30 p.m.

Sponsored by Varian, A Siemens Healthineers Company



My Year as the ASTRO Government Relations Fellow

BY MUSTAFA BASREE, MD, 2025 ASTRO GOVERNMENT RELATIONS FELLOW

MY JOURNEY FROM IRAQ TO THE CORRIDORS and small rooms of Capitol Hill to becoming a radiation oncologist in the United States has instilled in me a profound commitment to patient care and advocacy. Growing up amidst the instability of war taught me the importance of compassion and resilience, qualities that I strive to bring to my patients facing the uncertainties of cancer diagnosis and treatment. What I already knew even before connecting with ASTRO is that engagement matters. We are a small specialty, a small society, who deliver life-saving radiation therapy to more than one million people in the U.S. every year. Advocacy helps connect ASTRO members, and the patients we care for, to key political issues that affect how we deliver care every single day. Drawing from an early curiosity in politics in medical school, I welcomed the opportunity to apply for ASTRO's 2025 ASTRO Government Relations (GR) Fellowship to deepen my understanding of health policy and expand my advocacy skills.

I wanted from my Fellowship the insight to the legislative process and to learn how ASTRO influences policy decisions. I wanted to brainstorm strategies to maintain engagement among residents and early career attendings in ASTRO's advocacy initiatives and to help with messaging for advocacy and ASTRO PAC participation. I had travelled to Washington, DC, for direct lobbying previously in medical school, and so I was also excited to go to Advocacy Day, which I attended in 2023, 2024 and this past May. Earlier this month, I spent an additional week with the Government Relations team at ASTRO headquarters and had lunch with ASTRO CEO Vivek Kavadi, MD, MBA, FASTRO. Dr. Kavadi asked me to reflect and consider how to take my passion and experiences here through my early career and build. I am starting that build now by sharing what I learned:

Advocacy only works when members show up.

Our Advocacy team cannot do their job without communication and engagement from us. They need our help with prewritten appeal letters. They cannot help us navigate CMS coding changes and updates; they cannot help us navigate the changing landscape of government funding for cancer research programs; and they cannot help us relieve the stress of Medicare undervaluing our incredibly valuable, efficient, life-saving treatment to seniors. Advocacy needs all — both active residents as well as faculty members (early career and established) to inform the work in DC that certainly impacts our day-to-day work in clinic. Part of why I enjoyed my time in DC was understanding that much of what Advocacy does is about conveying what we do (and the value of it), by sharing stories to policymakers and lawmakers in a way that resonates with them. It is not spin-doctoring. It is nuanced and about building relationships with congressional members and their staff. It is about us, radiation oncologists, having a seat at the table.

I had wonderful sessions on behalf of my patients, connecting over coffee with Senate and House Chiefs of Staff where I was asked specifically about my

patients, our technology and struggles with prior authorization. Additional conversations were held at a fundraiser hosted by the ASTRO PAC for a member of the Energy and Commerce Subcommittee on Health and members of the House Ways and Means Committee — the exact group of lawmakers tasked with reviewing ROCR in Congress. I sat and talked with an appropriator (a member of the House Appropriations Committee, all government funding bills, including Labor H, which funds fundamental cancer research at NIH and NCI) about why the research and trials happening through government funding are critical; and explained why my experience as a cancer doctor motivated me to do more as an advocate. I talked for an hour with ASTRO staff about the development of the Coding Resource and how they engage every day with insurers on our behalf and the growing ASTRO library of direct resources that the Health Policy Committee volunteers work on throughout the year, like the upcoming ASTRO 2025 Virtual Coding and Coverage Seminar on December 6. Much of this time was thanks to our ASTRO PAC donations and existing relationships between key members of Congress. I saw how a campaign donation check gives us added opportunities to share our issues. I personally want ASTRO to continue being top-of-mind when lawmakers think of cancer care; I want our patients to be front-and-center when a lawmaker takes a vote on finally reforming prior authorization!

What I did not understand fully before my GR Fellowship this year and spending that week in DC was how important our engagement with ASTRO's Advocacy team is. I encourage you to visit the ASTRO PAC Pod Sunday through Tuesday in the lobby near registration. Staff and physician leaders are available there to discuss ROCR and other policy issues impacting radiation oncology and our patients. Take advantage of this opportunity to meet the Advocacy team and colleagues at the ASTRO PAC Pod!

From Medicare reimbursement, to government investment in foundational cancer research and clinical trials, our ASTRO staff are representing our work to lawmakers every day. I am challenging you to engage with them through committee volunteer work and through streamlined grassroots action when called upon. Support our advocates to be the experts we need advocating on our behalf. And have a watchful eye when stepping onto Constitution Avenue with aforementioned advocates — sometimes ASTRO's lobbyist Courtney Williams doesn't look both ways. 🇺🇸

EDU 17 – 2025 Advocacy Update
Monday, September 29 | 8:00 a.m. - 9:00 a.m.
📍 Room 159

Don't miss the 2025 ASTRO Advocacy Update for an opportunity to better understand how ASTRO advocates for policies that benefit radiation oncology on Capitol Hill. Learn how to engage in the process and become acquainted with the policy priorities that ASTRO is pursuing, including the Radiation Oncology Case Rate program.

2026  **ASTRO
ADVOCACY
DAY**

SAVE THE DATE:
APRIL 27-28, 2026

Royal Sonesta Washington, DC Capitol Hill
Washington, DC

astro.org/AdvocacyDay

Brachytherapy Workshop continued from front page


In addition to skill development, the three-hour workshop featured lecture components. Leading off the lecture portion, ABS President-elect Kristin Bradley, MD, University of Wisconsin, discussed the essentials of endometrial cancer brachytherapy. Dr. Bradley spoke about selecting, placing and planning with the “right” applicator for endometrial cancer, with a focus on intrauterine tandem and cylinder-based workflows and troubleshooting common placement issues.

Allison Garda, MD, Mayo Clinic, then reviewed the best practices in cervical brachytherapy. Dr. Garda providing information on applicator selection, walking participants through scenarios on when to use tandem and ring versus interstitial insertion techniques, and how to optimize geometry for dosimetric coverage.

The next half of the lecture segment focused on prostate brachytherapy. Marisa Kollmeier, MD, Memorial Sloan Kettering Cancer Center, presented the essentials of LDR prostate implants, leading participants through the step-by-step process of permanent seed implant brachytherapy. Dr. Kollmeier discussed pre-planning, intraoperative seed placement, and technical considerations for successful outcomes.

ABS President Mitchell Kamrava, MD, Cedars Sinai Medical Center, presented on the essentials of HDR prostate implants. Dr. Kamrava offered practical insights into HDR prostate brachytherapy workflow, including catheter insertion techniques, image guidance, and common pitfalls in planning and delivery.

This year’s workshop surpassed all expectations with regard to attendance and engagement, demonstrating how productive, thoughtful collaboration can lead to reimagined educational opportunities. 



Congratulations to the 2025 ASTRO-BCRF Annual Meeting Trainee Travel Award Recipients!

We are pleased to announce the selection of 10 recipients for the 2025 ASTRO-BCRF Trainee Travel Awards. These awards are designed to foster trainee engagement, education and professional growth by providing financial assistance to help offset the costs associated with attending the ASTRO Annual Meeting.



Opeoluwa Abraham Akerele, BS
Institution: Tulane University School of Medicine



Nahid Howard, MS
Institution: College of Osteopathic Medicine of the Pacific



Oluwatosin Ayeni, MBChB, PhD
Institution: University of Witwatersrand



Gene Lamanilao, MD
Institution: University of California, San Diego Health



Ariel Raimundo Choi, MD
Institution: Atrium Health Wake Forest Baptist Medical Center



Morgan Levy, MD, MPH
Institution: University of Kentucky Medical Center



Jonathan Cummock, BS
Institution: Texas A&M University College of Medicine



Juliana Runnels, MD
Institution: Mount Sinai



Jacob Elnaggar, PhD
Institution: Louisiana State University Health Sciences Center



Sabi Shrestha, MD
Institution: University of Texas Health, San Antonio

ASTRO SPEED MENTORING

SCHEDULE

**JOIN US
TODAY!**

SUNDAY, SEPTEMBER 28

9:30 a.m. - 10:30 a.m. | 📍 Early Career and Mentoring Lounge

SPECIAL SESSION FOR MEDICAL STUDENTS

Table 1 A Career in Radiation Oncology: Things to Consider



Malcolm Mattes, MD

Table 2 Away Rotations and Research Time: Pros and Cons



Gabrielle Peters, MD



Albert Attia, MD

Table 3 How to Ace the Interview and Understanding Signaling




Shane Neibart,
MD, MS



Steve Braunstein,
MD, PhD

Table 4 Navigating the Application Process



Mustafa Basree, MD



Nima Nabavizadeh,
MD

SPECIAL SESSION FOR INTERNATIONAL STUDENTS

Table 1 Building Clinical and Research Collaborations Across Borders



Anuja Jhingran, MD,
FASTRO



Simon Lo, MD, PhD,
ChB, FASTRO

Table 2 How to Get Started in Research, Finding Mentors



Surbhi Grover,
MD, MPH



Zachary Morris,
MD, PhD

Table 3 Locating Clinical Rotation Opportunities for International Physicians



Dayssy Alexandra
Diaz Pardo, MD, MS



Tamer Refaat, MD,
PhD, MS

Table 4 The Value of AI in Radiation Oncology 101



Gustavo Sarria, MD



Mohamed Abazeed,
MD, PhD

Best™ Integrated Brachytherapy Solutions

BEST MEDICAL is the only company that makes custom seeds and strands to meet your exact specifications—shipped within 24 hours, 7 days a week, sterile and non-sterile!

You don't go to a shoe store and cut your feet to fit the shoe they have in stock—then why compromise when it comes to improving the clinical outcome for your patient?

Best™ medical international

A TEAMBEST GLOBAL COMPANY



Best™ Esophageal Brachytherapy Applicator



Best™ Breast Double-Balloon Brachytherapy Applicator

Best™ Palladium-103 Seed



Best™ Iodine-125 Seed



Best™ Fiducial Markers



Best™ Localization Needles with I-125 Seeds



Best™ Treatment Planning System




Best™ HDR Remote Afterloader



For all radioactive sources

BestMick Applicator

BestMick 10/15/20/25 Cartridges




Best™ Kobold Henschke Tandem and Ovoid Applicator

Best™ Kobold Tandem and Ring Applicator

Best™ Kobold Fletcher Tandem and Ovoid Applicator

Best™ Templates



Portable Dosimetry System

mobileMOSFET Wireless Dosimetry System



Best™ Localization Marker Ribbon



Best™ Localization Marker Cable



Best™ Stepper/Stabilizer



Best™ GammaBeam™ 300-100 CM Equinox™ Teletherapy System with Avanza 6D Patient Positioning Table



Teletherapy System Upgrade Kit for all old Theratron units, 80 or 100 cm including IMRT capabilities with built in or external MLC



Novoste™ Beta-Cath™ 3.5 System



Best™ Theratronics

A TEAMBEST GLOBAL COMPANY

www.theratronics.ca

*Certain products shown are not available for sale currently. TeamBest Global Companies ©2025

Best™ vascular

A TEAMBEST GLOBAL COMPANY